Voluntary announcement - results of a phase i/ii clinical study of JSKN033 in patients with cc following failure of standard treatment were presented at the 2026 esmo congress as a rapid oral presentation
Filed with HKEX · Stock code 9966 ·
6ix is reading this filing.
View original source (HKEXnews)Alphamab Oncology on 6ix
Earlier from Alphamab Oncology
- Voluntary announcement - latest research results of two phase iii clinical studies of anbenitamab (KN026) were presented at the 2026 esmo congress as lba oral presentations
- Discloseable transaction - exercise of warrant to subscribe for preferred stock of pathos AI, inc.
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- 2026 Interim report
Later from Alphamab Oncology
- Voluntary announcement - latest research updates of JSKN003 presented at the 2026 esmo congress
- Grant of award shares under the restricted share award scheme
- Voluntary announcement - first patient dosed in phase iii clinical study of JSKN033 monotherapy for the treatment of cervical cancer
- Supplementary announcement on discloseable transaction
Follow Alphamab Oncology into a list and get an email when it puts out news.
Follow Alphamab Oncology